Comparative Analysis of Clinical Efficacy and Safety of Local Citrate Anticoagulation and Systemic Low-molecular-weight Heparin Anticoagulation in CRRT of Patients with Severe Tuberculosis
Objective:To compare the clinical efficacy and safety of local citrate anticoagulation and systemic low-molecular-weight heparin anticoagulation in CRRT for patients with severe tuberculosis.Methods:From October 2021 to September 2023,60 patients with severe tuberculosis who were treated with CRRT in our hospital were selected and divided into the observation group(local citrate anticoagulation)and the control group(systemic low-molecular-weight heparin anticoagulation),30 patients in each group.Compare the blood routine,liver and kidney function indicators,prognosis level,and incidence of complications between the two groups.Result:After treatment,PLT levels decreased in both groups of patients,while INR and APTT levels increased,with statistical significance(P＜0.05);After treatment,the Scr,BUN levels,SOFA,and APACHE Ⅱ scores of both groups of patients decreased,and there was a significant difference between the observation group and the control group(P＜0.05);The service life of the observation group fiilter was higher than that of the control group,and the incidence of bleeding was lower than that of the control group(P＜0.05).Conclusion:For severe tuberculosis patients,local citrate anticoagulation is better,while local citrate anticoagulation can improve the renal function,improve the prognosis of patients,improve the service life of the filter,and reduce the incidence of bleeding.
Local citrate anticoagulationWhole body low molecular weight heparin anticoagulationSevere tuberculosisContinuous renal replacement therapy
NETL
NSTL
万方数据
